Pharmacology and safety of tofacitinib in ulcerative colitis.

Abstract

The use of Janus kinase (JAK) inhibitors is a new approach in the therapy of inflammatory diseases with immune base. Tofacitinib is one of these inhibitors targeting JAK1 and JAK3, and its efficacy has been demonstrated in the treatment of moderate to severe ulcerative colitis (UC). It is a small synthetic molecule administered orally, with a fast bioavailability and elimination rate, predictable pharmacokinetics and lack of immunogenicity, which are convenient characteristics for both efficacy and safety. This article reviews the pharmacological characteristics of tofacitinib and its safety profile.

• Authors: Antonio López-Sanromán, Juan V Esplugues, Eugeni Domènech
• Journal: Gastroenterologia y hepatologia (Gastroenterol Hepatol) Vol. 44 Issue 1 Pg. 39-48 (Jan 2021) ISSN: 0210-5705 [Print] Spain
• Vernacular Title: Farmacología y seguridad de tofacitinib en colitis ulcerosa.
• PMID: 32829958 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved.

Chemical References

• Herpes Zoster Vaccine
• Janus Kinase Inhibitors
• Piperidines
• Pyrimidines
• tofacitinib
• JAK1 protein, human
• JAK3 protein, human
• Janus Kinase 1
• Janus Kinase 3

Topics

• Arthritis, Rheumatoid
• Colitis, Ulcerative (drug therapy)
• Drug Interactions
• Herpes Zoster (chemically induced)
• Herpes Zoster Vaccine (administration & dosage)
• Humans
• Janus Kinase 1 (antagonists & inhibitors)
• Janus Kinase 3 (antagonists & inhibitors)
• Janus Kinase Inhibitors (adverse effects, pharmacokinetics, pharmacology)
• Neoplasms (immunology)
• Piperidines (adverse effects, pharmacokinetics, pharmacology)
• Pyrimidines (adverse effects, pharmacokinetics, pharmacology)
• Venous Thromboembolism (chemically induced)